

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
<http://www.daiichisankyo.com/>

Revision to Reorganization of its Research & Development Structure

Tokyo, Japan (December 2, 2015) - Daiichi Sankyo Company, Limited has announced the following revision to the “Reorganization of its Research & Development Structure” announcement originally disclosed at 3:00pm JST on Tuesday, December 1, 2015.

Revised Item

Before

2nd Line: U3 Pharma GmbH (Munich, Germany; hereinafter, U3)

After

2nd Line: U3 Pharma GmbH (Martinsried, Germany; hereinafter, U3)